IMPROVE™ observational study of biphasic insulin aspart 30/70 in patients with Type 2 diabetes mellitus

References

• Leahy JL. Pathogenesis of Type 2 diabetes mellitus. Arch. Med. Res.36, 197–209 (2005).
   PubMed Web of Science ®Google Scholar
• Bell DS. Importance of postprandial glucose control. South. Med. J.94, 804–809 (2001).
   PubMed Web of Science ®Google Scholar
• Coates PA, Ollerton RL, Luzio SD, Ismail I, Owens DR. A glimpse of the ‘natural history’ of established Type 2 (non-insulin dependent) diabetes mellitus from the spectrum of metabolic and hormonal responses to a mixed meal at the time of diagnosis. Diabetes Res. Clin. Pract.26, 177–187 (1994).
   PubMed Web of Science ®Google Scholar
• Polonsky KS, Given BD, Hirsch LJ et al. Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus. N. Engl. J. Med.318, 1231–1239 (1988).
   PubMed Web of Science ®Google Scholar
• Polonsky KS, Sturis J, Bell GI. Seminars in medicine of the Beth Israel Hospital, Boston. Non-insulin-dependent diabetes mellitus – a genetically programmed failure of the β cell to compensate for insulin resistance. N. Engl. J. Med.334, 777–783 (1996).
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). Lancet352, 837–853 (1998).
   PubMed Web of Science ®Google Scholar
• Stratton IM, Adler AI, Neil HA et al. Association of glycaemia with macrovascular and microvascular complications of Type 2 diabetes (UKPDS 35): prospective observational study. BMJ321, 405–412 (2000).
   PubMed Web of Science ®Google Scholar
• Mudaliar S, Edelman SV. Insulin therapy in Type 2 diabetes. Endocrinol. Metab. Clin. North Am.30, 935–982 (2001).
   PubMed Web of Science ®Google Scholar
• Ilag LL, Kerr L, Malone JK, Tan MH. Prandial premixed insulin analogue regimens versus basal insulin analogue regimens in the management of Type 2 diabetes: an evidence-based comparison. Clin. Ther.29(6 Pt 1), 1254–1270 (2007).
   Web of Science ®Google Scholar
• Brunton S. Insulin regimens for Type 2 diabetes mellitus. J. Fam. Pract.55, 10S–17S (2006).
   Google Scholar
• Nathan DM, Buse JB, Davidson MB et al. Medical management of hyperglycemia in Type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care32, 193–203 (2009).
   PubMed Web of Science ®Google Scholar
• Hermansen K, Colombo M, Storgaard H, Østergaard A, Kølendorf K, Madsbad S. Improved postprandial glycemic control with biphasic insulin aspart relative to biphasic insulin lispro and biphasic human insulin in patients with Type 2 diabetes. Diabetes Care25, 883–888 (2002).
   PubMed Web of Science ®Google Scholar
• Boehm BO, Home PD, Behrend C, Kamp NM, Lindholm A. Premixed insulin aspart 30 vs. premixed human insulin 30/70 twice daily: a randomized trial in Type 1 and Type 2 diabetic patients. Diabet. Med.19, 393–399 (2002).
   PubMed Web of Science ®Google Scholar
• Garber AJ, Ligthelm R, Christiansen JS, Liebl A. Premixed insulin treatment for Type 2 diabetes: analogue or human? Diabetes Obes. Metab.9, 630–639 (2007).
   PubMed Web of Science ®Google Scholar
• Qayyum R, Bolen S, Maruthur N et al. Systematic review: comparative effectiveness and safety of premixed insulin analogues in Type 2 diabetes. Ann. Intern. Med.149, 549–559 (2008).
   PubMed Web of Science ®Google Scholar
• Cucinotta D, Russo GT. Biphasic insulin aspart in the treatment of Type 2 diabetes mellitus. Expert Opin. Pharmacother.10, 2905–2911 (2009).
   PubMed Web of Science ®Google Scholar
• Garber AJ, Wahlen J, Wahl T et al. Attainment of glycaemic goals in Type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (the 1–2–3 study). Diabetes Obes. Metab.8, 58–66 (2006).
   PubMed Web of Science ®Google Scholar
• Raskin P, Allen E, Hollander P et al. Initiating insulin therapy in Type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care28, 260–265 (2005).
   PubMed Web of Science ®Google Scholar
• Kann PH, Wascher T, Zackova V et al. Starting insulin therapy in Type 2 diabetes: twice-daily biphasic insulin aspart 30 plus metformin versus once-daily insulin glargine plus glimepiride. Exp. Clin. Endocrinol. Diabetes114, 527–532 (2006).
   PubMed Web of Science ®Google Scholar
• Malone JK, Kerr LF, Campaigne BN, Sachson RA, Holcombe JH. Combined therapy with insulin lispro Mix 75/25 plus metformin or insulin glargine plus metformin: a 16-week, randomized, open-label, crossover study in patients with Type 2 diabetes beginning insulin therapy.Clin. Ther.26, 2034–2044 (2004).
   PubMed Web of Science ®Google Scholar
• Wenying Y, Qiuhe J, Dalong Z et al. Biphasic insulin aspart 30 three times daily is more effective than a twice-daily regimen, without increasing hypoglycemia, in Chinese subjects with Type 2 diabetes inadequately controlled on oral antidiabetes drugs.Diabetes Care31, 852–856 (2008).
   Google Scholar
• Bebakar WM, Chow CC, Kadir KA, Suwanwalaikorn S, Vaz JA, Bech OM. Adding biphasic insulin aspart 30 once or twice daily is more efficacious than optimizing oral antidiabetic treatment in patients with Type 2 diabetes. Diabetes Obes. Metab.9, 724–732 (2007).
   PubMed Web of Science ®Google Scholar
• Kilo C, Mezitis N, Jain R, Mersey J, McGill J, Raskin P. Starting patients with Type 2 diabetes on insulin therapy using once-daily injections of biphasic insulin aspart 70/30, biphasic human insulin 70/30, or NPH insulin in combination with metformin. J. Diabetes Complicat.17, 307–313 (2003).
   PubMed Web of Science ®Google Scholar
• Rodbard HW, Blonde L, Braithwaite SS et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr. Pract.13(Suppl. 1), 1–68 (2007).
   PubMedGoogle Scholar
• European Diabetes Policy Group. A desktop guide to Type 2 diabetes mellitus. Diabet. Med.16, 716–730 (1999).
   PubMed Web of Science ®Google Scholar
• Khutsoane D, Sharma SK, Almustafa M et al. Biphasic insulin aspart 30 treatment improves glycaemic control in patients with Type 2 diabetes in a clinical practice setting: experience from the PRESENT study. Diabetes Obes. Metab.10, 212–222 (2008).
   PubMed Web of Science ®Google Scholar
• Valensi P, Benroubi M, Borzi V et al. The IMPROVE study – a multinational, observational study in Type 2 diabetes: baseline characteristics from eight national cohorts. Int. J. Clin. Pract.62, 1809–1819 (2008).
   PubMed Web of Science ®Google Scholar
• Valensi P, Benroubi M, Borzi V et al. Initiating insulin therapy with, or switching existing insulin therapy to, biphasic insulin aspart 30/70 (NovoMix 30) in routine care: safety and effectiveness in patients with Type 2 diabetes in the IMPROVE observational study. Int. J. Clin. Pract.63, 522–531 (2009).
   PubMed Web of Science ®Google Scholar
• Wenying Y, Benroubi M, Borzi V et al. Improved glycaemic control with BIAsp 30 in insulin-naive Type 2 diabetes patients inadequately controlled on oral antidiabetics: subgroup analysis from the IMPROVE study. Curr. Med. Res. Opin.25, 2643–2654 (2009).
   PubMed Web of Science ®Google Scholar
• Gumprecht J, Benroubi M, Borzi V et al. Intensification to biphasic insulin aspart 30/70 (BIAsp 30, NovoMix 30) can improve glycaemic control in patients treated with basal insulins: a subgroup analysis of the IMPROVE observational study. Int. J. Clin. Pract.63, 966–972 (2009).
   PubMed Web of Science ®Google Scholar
• Shah S, Benroubi M, Borzi V et al. Safety and effectiveness of biphasic insulin aspart 30/70 (NovoMix 30) when switching from human premix insulin in patients with Type 2 diabetes: subgroup analysis from the 6-month IMPROVE observational study. Int. J. Clin. Pract.63, 574–582 (2009).
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care29(Suppl. 1), S43–S48 (2006).
   PubMed Web of Science ®Google Scholar
• American Association of Clinical Endocrinologists. The American Association of Clinical Endocrinologists Medical Guidelines for the Management of Diabetes Mellitus: the AACE system of intensive diabetes self-management – 2000 update. Endocr. Pract.6, 43–84 (2000).
   PubMedGoogle Scholar
• American Diabetes Association. Standards of medical care in diabetes – 2008. Diabetes Care31(Suppl. 1), S12–54 (2008).
   PubMed Web of Science ®Google Scholar
• Luzio S, Dunseath G, Peter R, Pauvaday V, Owens DR. Comparison of the pharmacokinetics and pharmacodynamics of biphasic insulin aspart and insulin glargine in people with Type 2 diabetes. Diabetologia49, 1163–1168 (2006).
   PubMed Web of Science ®Google Scholar
• Jacobsen LV, Sogaard B, Riis A. Pharmacokinetics and pharmacodynamics of a premixed formulation of soluble and protamine-retarded insulin aspart. Eur. J. Clin. Pharmacol.56, 399–403 (2000).
   PubMed Web of Science ®Google Scholar
• Weyer C, Heise T, Heinemann L. Insulin aspart in a 30/70 premixed formulation. Pharmacodynamic properties of a rapid-acting insulin analog in stable mixture. Diabetes Care20, 1612–1614 (1997).
   PubMed Web of Science ®Google Scholar
• Heise T, Eckers U, Kanc K, Nielsen JN, Nosek L. The pharmacokinetic and pharmacodynamic properties of different formulations of biphasic insulin aspart: a randomized, glucose clamp, crossover study. Diabetes Technol. Ther.10, 479–485 (2008).
   PubMed Web of Science ®Google Scholar
• Turnbull FM, Abraira C, Anderson RJ et al. Intensive glucose control and macrovascular outcomes in Type 2 diabetes. Diabetologia52(11), 2288–2298 (2009).
   PubMed Web of Science ®Google Scholar
• Gerstein HC, Miller ME, Byington RP et al.; the ACCORD (Action to Control Cardiovascular Risk in Diabetes) Study Group. Effects of intensive glucose lowering in Type 2 diabetes. N. Engl. J. Med.358(24), 2545–2559 (2008).
   PubMed Web of Science ®Google Scholar
• Kosiborod M, Inzucchi SE, Goyal A et al. Relationship between spontaneous and iatrogenic hypoglycemia and mortality in patients hospitalized with acute myocardial infarction. JAMA301(15), 1556–1564 (2009).
   PubMed Web of Science ®Google Scholar
• Liebl A, Prager R, Binz K, Kaiser M, Bergenstal R, Gallwitz B. Comparison of insulin analogue regimens in people with Type 2 diabetes mellitus in the PREFER study: a randomized controlled trial. Diabetes Obes. Metab.11, 45–52 (2009).
   PubMed Web of Science ®Google Scholar
• Jang HC, Guler S, Shestakova M. When glycaemic targets can no longer be achieved with basal insulin in Type 2 diabetes, can simple intensification with a modern premixed insulin help? Results from a subanalysis of the PRESENT study. Int. J. Clin. Pract.62, 1013–1018 (2008).
   PubMed Web of Science ®Google Scholar
• Shestakova M, Sharma SK, Almustafa M et al. Transferring Type 2 diabetes patients with uncontrolled glycaemia from biphasic human insulin to biphasic insulin aspart 30: experiences from the PRESENT study. Curr. Med. Res. Opin.23, 3209–3214 (2007).
   PubMed Web of Science ®Google Scholar
• Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care27, 1047–1053 (2004).
   PubMed Web of Science ®Google Scholar